OA20623A - Foam-forming compositions for delivering an active to a body cavity. - Google Patents
Foam-forming compositions for delivering an active to a body cavity. Download PDFInfo
- Publication number
- OA20623A OA20623A OA1201900457 OA20623A OA 20623 A OA20623 A OA 20623A OA 1201900457 OA1201900457 OA 1201900457 OA 20623 A OA20623 A OA 20623A
- Authority
- OA
- OAPI
- Prior art keywords
- foam
- forming composition
- cavity
- body cavity
- forming
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 170
- 239000006260 foam Substances 0.000 claims abstract description 197
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 54
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 47
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 239000004604 Blowing Agent Substances 0.000 claims abstract description 15
- 239000002537 cosmetic Substances 0.000 claims abstract description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 103
- 150000002632 lipids Chemical class 0.000 claims description 55
- 239000003380 propellant Substances 0.000 claims description 50
- 238000002844 melting Methods 0.000 claims description 30
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 21
- 239000007787 solid Substances 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 210000001519 tissues Anatomy 0.000 claims description 17
- 238000007664 blowing Methods 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- DCBSHORRWZKAKO-UHFFFAOYSA-N 1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 claims description 8
- ARIWANIATODDMH-UHFFFAOYSA-N Monolaurin Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drugs Drugs 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 201000004681 psoriasis Diseases 0.000 claims description 5
- 210000003708 Urethra Anatomy 0.000 claims description 4
- 206010046543 Urinary incontinence Diseases 0.000 claims description 4
- 210000000214 Mouth Anatomy 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 210000003928 Nasal Cavity Anatomy 0.000 claims description 2
- 210000003932 Urinary Bladder Anatomy 0.000 claims description 2
- 230000002682 anti-psoriatic Effects 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 239000008246 gaseous mixture Substances 0.000 claims description 2
- 230000002040 relaxant effect Effects 0.000 claims description 2
- 206010067647 Delivery Diseases 0.000 claims 1
- 230000001078 anti-cholinergic Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 42
- 210000003491 Skin Anatomy 0.000 abstract description 35
- 200000000019 wound Diseases 0.000 abstract description 10
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 abstract description 6
- -1 and a medical Substances 0.000 abstract description 4
- 239000000155 melt Substances 0.000 abstract description 2
- 230000036760 body temperature Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 60
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 35
- 239000007789 gas Substances 0.000 description 21
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 21
- 239000004310 lactic acid Substances 0.000 description 21
- 235000014655 lactic acid Nutrition 0.000 description 21
- 239000002253 acid Substances 0.000 description 14
- 238000002425 crystallisation Methods 0.000 description 14
- 230000005712 crystallization Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 12
- IJDNQMDRQITEOD-UHFFFAOYSA-N butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 11
- 239000003381 stabilizer Substances 0.000 description 11
- 102000016938 EC 1.11.1.6 Human genes 0.000 description 10
- 108010053835 EC 1.11.1.6 Proteins 0.000 description 10
- 239000001273 butane Substances 0.000 description 10
- 239000006071 cream Substances 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000010583 slow cooling Methods 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 10
- 239000001294 propane Substances 0.000 description 9
- 238000007792 addition Methods 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 238000005187 foaming Methods 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 229940105657 CATALASE Drugs 0.000 description 7
- 210000001215 Vagina Anatomy 0.000 description 7
- 230000003115 biocidal Effects 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 206010018612 Gonorrhoea Diseases 0.000 description 6
- 229940079864 SODIUM STANNATE Drugs 0.000 description 6
- 229940039790 Sodium Oxalate Drugs 0.000 description 6
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L Sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 6
- FQENQNTWSFEDLI-UHFFFAOYSA-J Tetrasodium pyrophosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 6
- 235000019400 benzoyl peroxide Nutrition 0.000 description 6
- 201000004624 dermatitis Diseases 0.000 description 6
- TVQLLNFANZSCGY-UHFFFAOYSA-N disodium;dioxido(oxo)tin Chemical compound [Na+].[Na+].[O-][Sn]([O-])=O TVQLLNFANZSCGY-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 229960004889 salicylic acid Drugs 0.000 description 6
- 229940048086 sodium pyrophosphate Drugs 0.000 description 6
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 6
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 6
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 5
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 5
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 5
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 5
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 5
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 229940079866 intestinal antibiotics Drugs 0.000 description 5
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 4
- 206010017533 Fungal infection Diseases 0.000 description 4
- 206010053317 Hydrophobia Diseases 0.000 description 4
- 229960004063 Propylene glycol Drugs 0.000 description 4
- 206010062167 Vaginitis bacterial Diseases 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 235000013772 propylene glycol Nutrition 0.000 description 4
- 230000001105 regulatory Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 229960004424 Carbon Dioxide Drugs 0.000 description 3
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 3
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 3
- 208000005679 Eczema Diseases 0.000 description 3
- RFVNOJDQRGSOEL-UHFFFAOYSA-N Glycol stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 3
- 208000001786 Gonorrhea Diseases 0.000 description 3
- 210000004379 Membranes Anatomy 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010046914 Vaginal infection Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004411 aluminium Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 210000004027 cells Anatomy 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- 231100001003 eczema Toxicity 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 229940064004 Antiseptic throat preparations Drugs 0.000 description 2
- 241001480043 Arthrodermataceae Species 0.000 description 2
- LWQQLNNNIPYSNX-UROSTWAQSA-N Calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 206010014013 Ear infection Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229960001664 Mometasone Drugs 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 229940066842 Petrolatum Drugs 0.000 description 2
- VZJVWSHVAAUDKD-UHFFFAOYSA-N Potassium permanganate Chemical compound [K+].[O-][Mn](=O)(=O)=O VZJVWSHVAAUDKD-UHFFFAOYSA-N 0.000 description 2
- 229940048084 Pyrophosphate Drugs 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J Pyrophosphate Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 206010040490 Sexually transmitted disease Diseases 0.000 description 2
- 208000006379 Syphilis Diseases 0.000 description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N Terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 2
- 206010068760 Ulcers Diseases 0.000 description 2
- 229940044952 Vaginal Foam Drugs 0.000 description 2
- 208000010484 Vulvovaginitis Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000843 anti-fungal Effects 0.000 description 2
- 230000000845 anti-microbial Effects 0.000 description 2
- 230000002421 anti-septic Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229960004649 calcipotriene Drugs 0.000 description 2
- 229960002882 calcipotriol Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 230000001010 compromised Effects 0.000 description 2
- 231100000406 dermatitis Toxicity 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000001771 impaired Effects 0.000 description 2
- 238000009114 investigational therapy Methods 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001717 pathogenic Effects 0.000 description 2
- 244000052769 pathogens Species 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000001850 reproductive Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960002722 terbinafine Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary Effects 0.000 description 2
- 239000000259 vaginal foam Substances 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N 1-Tetradecanol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-M 2-furoate Chemical compound [O-]C(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-M 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N CHEMBL1888176 Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- HXGBXQDTNZMWGS-RUZDIDTESA-N Darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 description 1
- 229960000935 Dehydrated Alcohol Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N Doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960005426 Doxepin Drugs 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- DCCSDBARQIPTGU-HSZRJFAPSA-N Fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 241000207201 Gardnerella vaginalis Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Incidol Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- PBAPPPCECJKMCM-IBGZPJMESA-N Mirabegron Chemical compound S1C(N)=NC(CC(=O)NC=2C=CC(CCNC[C@H](O)C=3C=CC=CC=3)=CC=2)=C1 PBAPPPCECJKMCM-IBGZPJMESA-N 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N Monoctanoin Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- 210000003097 Mucus Anatomy 0.000 description 1
- 229940120393 Myrbetriq Drugs 0.000 description 1
- 210000001331 Nose Anatomy 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 210000003800 Pharynx Anatomy 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229940068965 Polysorbates Drugs 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 208000006641 Skin Disease Diseases 0.000 description 1
- 206010040872 Skin infection Diseases 0.000 description 1
- FBOUYBDGKBSUES-VXKWHMMOSA-N Solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N Stearyl alcohol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 229940088594 Vitamin Drugs 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010047786 Vulvovaginal discomfort Diseases 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 150000001253 acrylic acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000840 anti-viral Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungals Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 229960004729 colecalciferol Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229960002677 darifenacin Drugs 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000002612 dispersion media Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 229960002978 fesoterodine Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960001551 mirabegron Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229940005943 ophthalmologic Antivirals Drugs 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 244000045947 parasites Species 0.000 description 1
- NPDODHDPVPPRDJ-UHFFFAOYSA-N permanganate Chemical compound [O-][Mn](=O)(=O)=O NPDODHDPVPPRDJ-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000646 scanning calorimetry Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008259 solid foam Substances 0.000 description 1
- 229960003855 solifenacin Drugs 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 201000009642 tinea barbae Diseases 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 229940026754 topical Antivirals Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960001491 trospium Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin D3 Drugs 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Abstract
Provided is a foam-forming formulation and method of administrating a medically active or cosmetic or reliving compound to the skin, to a would or to a body cavity. The foam-forming formulation contains monoglyceride crystals, a hydrophilic blowing agent in an amount to blow the foam-forming composition and form a foam, water, and a medical, cosmetic or reliving compound. The foam-forming composition is suitable application to skin, wounds and body cavities when blown to form the foam and the foam melts at a body temperature to release the content. Also provided is a foam-forming composition vehicle for delivering an active agent.
Description
FOAM-FORMING COMPOSITIONS FOR DELIVERING AN ACTIVE TO A BODY CAVITY
Field of the Invention.
The invention relates to foam-forming compositions containing crystalline lipids and methods for local delivery of medically active agents to skin or a body cavity. The invention also relates to a novel foam delivery System and method of delivery.
Background of the Invention.
We hâve found that topical and intracavital foam formulations are suitable for the delivery of medically active agents. A foam has several attractive properties in medical treatment since it has a capacity to spread over large surfaces and it has low density which makes administration to sensitive areas, such as wounds, infected or inflamed areas or postsurgery tissue of the skin less painful. Foam also spreads well in body cavities.
Monoglycerides hâve been used with lipid propellants. If however a lipid propellant is used in combination with crystalline monoglycerides we hâve found that the resulting product is inhomgenous and not crystalline. We hâve surprisingly found that if polar or hydrophilic propellants are used we can maintain the crystalline structure of the monoglycerides and the resulting product is stable and homogenous.
There are several problems associated with the delivery of drugs to a body cavity and to skin. One important issue is the distribution of the drug. Semisolid formulations, creams, gels and ointments are not able to generate uniform drug delivery to the body cavity area. Furthermore administration of semisolids to sensitive areas of the skin is less suited since the mechanical work to administer the product may create pain and discomfort. Foam formulations based on lipid crystalline formulations may be the solution for this problem. The treatment of infections and inflammations in the reproductive organs such as STI, sexually transmitted infections, bacterial vaginosis and vulvovaginitis is one area where the invented foam has advantages with respect to drug distribution and delivery. Also the treatment of vaginal discomfort such as malodour, pain, itch and increased vaginal fluid excrétion are problematic. The overuse of systemic treatment with active agents, such as 1 antibiotics, has led to development of résistance and the diversity of the diseases, which leads to the need for several treatments with different actives that increase the risk for maltreatment. The difficulty of diagnosing is another issue that can make thérapies inefficient. Local treatment has so far been inefficient. The reasons for the inefficacy of local treatment is partly lack of effective local agents but also ineffective surface cover of the local product. A gel product or a vagitorium does not deliver drug to the entire area in the reproductive organs.
Local treatment of diseases in body cavities such as vagina, urethra, ear, anus and the nasal cavity in general require treatment of the entire area in the body cavity. If only a part of the area is treated local infections and inflammations may remain partly untreated and will soon recover its original streght. Intra-cavital préparations such as gels, ointments, vagitories/suppositories and tablets hâve the draw back that only a minor part of the surface is treated. In the case of systemic delivery of active compounds by administration in body cavities the lack of surface coverage means that only a small and from time to time varying area is exposed. This will lead to an unpredictable drug uptake and to a variation in the biological response and medical effect, and risk for résistance development. In contrast, the présent novel delivery System is capable of treating the entire surface of a body cavity due to its solid crystalline structure in a composition selected to provide a mechanically stable foam. The body cavities may be natural or artificial body cavities, created by wounds or surgery.
Another aspect of of topical drug delivery where a foam is needed is administration to large and sensitive areas. The treatment of sensitive areas, as in dermatitis and in infected or chronic wounds, will benefit from a minimum of physical contact and here the use of the invented foam is bénéficiai for the patient and patient compliance.
The usefulness of using foams for the treatment of body cavities is described in Arzhavitina A, Steckel H. “Foams for pharmaceutical and cosmetic application”. Int J Pharm. 2010 Jul 15;394(1 -2): 1 -17. doi: 10.1016/j.ijpharm.2010.04.028. Epub 2010Apr29. Foam containing monoacylglycerides are not common. In US 4,684,479 the use of acylmonoglycerides in foams, formation of microbubbles, is described. There is no information on the melting point and the acylmonoglyceride is not in crystalline form. In US 5,554,315 the use of acylmonoglycerides to improve physical properties of foams based 2 on surfactants, polyoxyalkylene ethers are described. In US 5,693,258 the use of acylmonoglyceride polyoxyethylene dérivatives forfoams is described. The use of acylmonoglycerides alone or their crystals is not mentioned. In US 7,141,237 and US 7,374,747 the use of higher alcohols, C14 to C22, a small alcohol C1 to C6 water and a surfactant for the génération of a température sensitive foam is described. In the présentations of the invention no acylmonoglyceride is mentioned and the formulations contain a surfactant based on an ester of laurinmonoglyceride. In US 7,749,488, a foam consisting of éthanol, water, a surfactant, a pH adjusting compound and a propellant is described in the first claim. The surfactant is defined as a compound from the groups of block-co- polymers, fatty acid and/orfatty alcohol etoxylates, polysorbates and glycerol ester etoxylates. A person skilled in the art may add one or several of the surfactants of these groups to the invented composition for the purpose of improving physical properties, but the présent invention is based on the use of crystalline lipids and their melting at températures below 37°C, which is not disclosed in this patent. In US 8,193,244 the use of C12 monoacylglycerol in combination with long chain dibasic amino acid alkyl ester salts has been claimed as a synergistic antimicrobial combination, which is not relevant for a foam application. The use of C12 acylmonoglcyeride for the treatment of otitis has been described in US 8,476,319 but there is no teaching of the use of the acylmonoglyceride in crystalline form nor its melting.
In US 8,512,723 the use of C12 acylmonoglyceride is described. However, in this patent the product must contain at least 50% of hydrophobie compound and there is no teaching of the use of the acylmonoglyceride in crystalline form and/or its melting. In US 8,586,008 a foam fortopical purposes containing various medical agents is presented. The patent teaches that the melting point of this foam can be regulated with the presence of éthanol. In the invented formulation the melting température is regulated by the mixing proportions of acylmonoglycerides. The presence of éthanol increases solubility of the acylmonoglycerides, thereby inhibiting the formation of crystals that is important for the properties of the foam. The patent teaches away from using crystals in the formulation.
In (Tamarkin) WO2011039637 the main claim in this patent application is “ A substantially surfactant free foamable composition comprising: a) about 60% to about 95% by weight of a hydrophobie solvent, or about 1% to about 80%) by weight petrolatum and about 15% to about 94% by weight hydrophobie solvent, wherein if combined the total amount of hydrophobie solvent and petrolatum is at least about 60%> by weight”. This patent application does not teach the use of crystalline lipids in a water base to form a foam.
My previous application, published as U.S. serial No. 2016-0201186 on 14 July 2016, is incorporated herein by référencé.
There is a need for improvements in treating infections in body cavities, in wounds and on skin, especially under conditions where classical antibiotics may not be effective and/or where there is a risk for résistance development. There is a need for a product that can be administered immediately upon the discovery of an infection without any risk of creating antibiotic résistance to the infecting agent and with a high probability of efficient treatment irrespective of the nature the infecting agent, e.g. bacteria, virus, fungi and flagellâtes.
Another issue is the physical stability of the formulation during storage. If lipophilie propellants are used the monoglycerides will undesirably dissolve in the propellants. This will reduce the amount crystalline monoglycerides and phase séparation will occur. In fact the formulation will be in the form of a two phase System containing a lipid phase consisting of a solution of monoglycerides in the by pressure solidified propellants and a water phase containing water, crystalline monoglycerides with a hydrophilic surface and other hydrophilic éléments. When release from the compressed State the propellant will evaporate and leave a semisolid film of water and a mixture of crystalline and amorphous lipids. Nonlimiting examples of such unsuitable lipid propellants are propane, butane and isopropane. When such unsuitable propellants are used the stability of the foam is impaired and the foam forming capacity is compromised. A suitable propellant should be able to maintain the crystalline structure of the monoglycerides both in the container during shelf life and after having produced a foam. Examples of suitable propellants are polar and hydrophilic ones that as the main part contain air or gaseous mixture simulating air, oxygen, nitrogen, carbon dioxide. In the présent invention we demonstrated that the use of air and similar propellants are superior the use of lipid propellants. Another aspect of using air as propellant or foam forming agent is the possibility to form foams at low pressures or at ambient pressures. This property was discovered when formulations containing air were stored. Microscope investigation revealed stable air bubbles over time. This feature can be used to distribute foam products in non pressurized containers which is a large advantage from industial and safety point of view.
Suitable medically active agents are agents that are effective in the treatment of skin infections and inflammation, in the treatment of conditions in wounds and in body cavities. Non-limiting examples of medically active agents are anti-inflammatory agents, antibiotics, antivirals, antifungals, anti-psoriatic agents, agents for the control of humidity or pH in skin as well as agents for the treatment of acné.
Another issue in treating skin, open wounds or cavities of the body is the use of foreign matter. Lipid propellants exemplified by propane or butane are not physiological and such compounds are not suitable for human or animal use in body cavities.
Summaryofthe Invention.
The présent invention solves the problems mentioned hereing above by providing a dense and stable foam. The product is mixed with or pressurized by nonlipophillic gases to generate stable lipid crystals. The product is adapted for use on skin, in wounds or other skin areas with impaired protective function and in body cavities.
The présent invention comprises a suspension or a semisolid préparation containing crystalline monoglycerides, mixed with a propellant (blowing agent) to form foam. The mixing can be done under pressure, up to 10 bar, orduring ambient conditions 1 bar. By administering the product in the form of foam, the entire volume of the cavity or the entiry surface of the area can be filled. The foam is constructed to physically décomposé, melt, at a skin température and thereby the entire surface of the cavity will be treated.
The présent invention also relates to a novel foam-forming delivery System comprising solid crystals of lipids that décomposés (melts) at body température. The foam is strong and stable at sub décomposition (melting) températures thus being able to cover even the narrowest parts of the internai volume of body cavities or area to be treated on skin. Once the volume or area is covered by the foam, the foam is heated by the body or skin until the foam reaches a décomposition température and the crystals melt and the foam breaks due to the elevated température. The melted remains of the decomposed foam, a nonrunny viscous fluid, coat the tissues of the treated area. Such foam is useful for delivery of medically active agents to the skin and the interior of body cavities. The product can also be used for systemic delivery via body cavities or the skin.
The lipid crystal has a solid form that is sufficient to maintain a foam structure at a température below the body and skin températures (98.6°F or 37°C and 93.2°F or 34°C). The foam can be manufactured by two modes. One is during the manufacturing process by mixing polar gases into the product and the product is then stored in the form of a foam at normal pressure. The other way is to introduce a blowing gas into the formulation and to store the product at elevated pressure, up to 10 bar, in a pressurized can. The foam forming composition comprising lipid crystals and at least one active is stored, and a propellant can used to blow the foam-forming composition and form the foam during application to a cavity or to skin. Once the foam is in place, the foam is heated by the body. When the foam reaches a décomposition température (the décomposition température is less than or equal to the body/skin température), the lipid crystals melt and the foam breaks down releasing the trapped blowing gas and active agent from the foam to form a layer of active agent on exposed tissue within the cavity or the treated area.
The présent invention further relates to a method of administering locally or systemically active agents to tissues on the skin or within body cavities. As earlier described, there are several problems associated with dermal and intracavital drug administration. A solution to these problems is to deliver the medically active agent in the form of a foam of crystalline lipids that melt at body température. The foam has a structure, below the melting température, strong enough to allow the foam to be distributed into an entire volume of a cavity while at the same being able to adhéré to the entire surface once melted. The foam is also strong enough to allow administration to skin without imedeately breaking down.
The présent invention further relates to the foam forming composition, disclosed herein, in combination with a delivery device capable of generating a foam of the composition and comprising a foam guiding conduit adapted to provide delivery of the foam into a body cavity or a skin area. The conduit is generally adapted to enable administration initially to the parts of the body cavity furthest away from the entrance, e.g. having adéquate length, and therafter to the outer parts e.g. while withdrawing the conduit in a controlled and predetermined manner.
Objectives of the invention can be obtained by a foam-forming composition adapted for treating a disease on skin or in a body cavity comprising:
monoglyceride crystals in an amount to form a foam;
a nonlipophillic blowing agent in an amount to blow the foam-forming composition and form a foam;
at least one medical agent effective against diseases of the skin or body cavity; and water, wherein the foam-forming composition is configured for application to body cavity when blown or mixed to form the foam and the form dégradés at a body température to release the medically active agent. Ail % are by weight of the total composition unless otherwise stated.
Objectives of the inventions can also be obtained by a foam-forming pharmaceutical composition for delivering an active agent to a body cavity comprising:
water;
solid lipid crystals suspended in the water, the solid lipid crystals having a melting point in their crystalline State of less than 37°C and more than 25°C; and a propellant for blowing the composition and forming a foam, wherein the solid lipid crystals being présent in an amount to support a foam when the composition is blown by the propellant, and the composition is adapted for application to the body cavity when blown so that when the foam is heated by the body cavity the foam dégradés at the melting point and releases contents of the foam to tissues in the body cavity.
Objectives of the invention can also be obtained by adapting the composition of the foam such that upon melting it contacts the surface of the cavity to deliver the active principle and the contacting form is résistant to removal by flow of wound or vaginal fluids.
Objectives of the inventions are preferably obtained by guiding the delivery of the foam formed from the foam-forming compositions to a body cavity with a foam guiding conduit adapted to provide delivery to the entire body cavity.
Brief Description of the Drawings.
Fig. 1 is a picture of a foam formed according to Example 16.
Fig. 2 is a picture of the foam of Fig. 1 after 1 month of storage.
Detailed Description of the Invention.
Foam Formulations.
The présent invention can be a form that forms a foam when mixed with a blowing gas. This can be performed by adding the blowing gas during manufacture at normal pressure (1 bar ) while mixing and by packing the gas mixed product at normal pressure or by adding a blowing gas under pressure, up to 10 bar, and storing it in a pressurized container where the foam is mainly generated at the application of the product to skin or body cavities. The formulation is advantageously a suspension of lipid crystals and can be mixed or pressurized with a blowing gas to form a foam. In the présent formulation we hâve found that a préférable combination of two monoglycerides, C12 monolaurine and C14 monomyristine can create a foam that will décomposé when exposed to températures at skin or body termperature. This embodiment will describe the preferred use of this foam. However, the formulation can utilize any foam that will décomposé when exposed to human body températures, including the novel foam delivery System described herein, and convention foams. Thus, any suitable foam forming composition can be used, and the invention is not limited to the preferred examples disclosed herein.
In order to exercise a medical effect the formulation must be in physical contact with the affected tissue. Local formulations in the form of fluids and semisolids are only in contact with a minor part of the mucosal tissue and are thus not able to exercise its full effect. In the présent formulation the foam first fills the entire cavity or skin area and secondly the foam décomposés due to the melting of the monoglycerides by the body température. This way the entire inner surface of the treated area is covered and treated with the formulation when the foam décomposés and releases the active agent to the entire affected area.
A foam can be generated by addition of a propellant (blowing agent) suitable for human use, exemplified but not limited to air and carbondioxide. Any desired, suitable blowing agent can be used in an amount sufficient to provide the foam during application to the body cavity. An exemplary amount of propellant is amounts that ionduces a pressure from athmospheric pressure to 10 bar. The amount of propellant can dépend on the desired structure of the foam as evaluated by a skilled artisian.
Furthermore, the présent invention can contain an additional stabilizer in the form of crystalline lipids such as monoglycerides in the amount of 1 to 35 %. The monoglycerides are 1-Glycerolmonolaurate, C12, and 1-Glycerolmonomyristate, C14. The amount of and the ratio between C12 and C14 can be varied depending on the required viscosity of the final product. The ratio C12 to C14 can vary from 1 to 3 to 1 to 1 for a cream product and 1 to 3 to 1 to 0 for a lotion/spray form product with lower viscosity. The amount of lipids in a cream can vary between 15 and 35% while lotions and sprays has a préférable lipid content of 1 to 15%. The monoglycerides are in crystalline form in the final formulation. The manufacture of the monoglyceride crystalline dispersion is performed by heating ail components, see examples, to 70°C and cool at a fixed rate, 0.5 to 5°C per minute, until crystallisation starts at 30 to 39°C. Before or during the crystallization process gas can be mixed into the product by stirring of by the use of homogenizers. The gas will remain in the product during the rest of the production process and during packaging. Such products are not pressurized but a storage stable foam is formed.
In one embodiment of the novel foam delivery System, we hâve invented a formulation that in the presence of a propellant (blowing agent), such as a non- lipophilie gas , is able to form foams comprising (solid) lipid crystals. Such crystals may comprise single lipids or a mixture of lipids. Suitable lipids are phospholipids, mono and di acylglycerides. Nacetylethanolamides and esters of lactic acid and fatty acids. Since the lipids are in their crystalline State, the foam will maintain its structure while filling the body cavity. The lipids should be at least partly in their crystalline State, more préférable to 50% and even more préférable to 70% and most preferably to 80% determined by scanning calorimetry.
Crystalline lipids are defined by a continuous repeated structure in three dimensions but the nature of the répétition may not be the same in ail directions. The crystals may contain bilayers of water and lipid creating a repeated structure of water and lipid layers in one direction and lipid crystals in two directions. An easy way to detect crystallinity is to study biréfringence in microscope. For example, a définition of a lipid lamellar crystal is a solid crystal with three dimensional continuity having the same repeated cells in two dimensions, but a different one in the third dimension, from Small, The lipid handbook, which can be established by wide angle X-ray ref. The crystallinity of monoglycerides in the compositions can be determined by differential scanning calorimetry, DSC. The transfer from solid liquid crystals is exothermic and gives rise to a release of energy. This can be determined by a scanning calorimeter.
There are several advantages associated with the use of (solid) lipid crystals. Since the crystalline State in general is the lowest energetic State very little will happen with the structure during storage. In contrast to émulsions and liquid crystals which are changing overtime by crystallization, sédimentation or coalescence, the solid lipid crystalline structures does not change overtime in a pharmaceutical perspective. Stable constituents are regarded as a large advantage in the development of pharmaceutical products.
Another embodiment of the invention is the ability of the foam to décomposé (melt) at skin température or in the body cavity. When lipid crystals melt the gas will be released and the foam will décomposé to form a solution that can coat the tissue on skin or in the body cavity. The content of the foam, active agents, pH modifying agents, etc. will be released to the tissue and the product can exert its effect. Such foam should preferably melt at a température of 25 to 37°C more préférable at 30 to 37°C and most preferably at 32 to 37°C.
Yet another embodiment of the invention is the ability to fill the internai volume of a body cavity and to cover a surface once melted to enable medically active agents to be in the formulation to make good contact with the mucosal membrane at the site of administration.
The foam delivery formulations according to the présent invention can comprise a solvent or dispersion media, preferably water. The water can make up the balance of the composition. The solid lipid crystals are présent in an amount suitable forforming the foam, for example from 0.5 and 30 %. The composition can also include pH and tonicity regulating compounds and pharmaceutically active agents. The formulations can also contain agents for improving foam properties and non-limiting examples are nonionic surfactants of high HLB. Examples of such surfactants are esters of fatty acids and alcohols or saccharides of polar nature.
In a typical but non-limiting procedure the solid lipid crystals are manufactured by heating the lipid(s) in water to 70 to 75°C to melt the lipids followed by cooling to room température te solidify the lamellar crystals. The medically active agent can be added prior to, during or after heating and even after cooling. The cooled dispersion of crystals can then be diluted, if required, and mixed with other agents prior to packing in a pressurized container. Nonlimiting examples of such agents are pH modifyers, solvents, viscosity enhancers, Chemical and physical stabilizers,humectants, émollients and preservatives.
In a further embodiment of the invention, the product can be presented in a pressurized container containing a suitable propellant (blowing agent). Non-limiting examples of suitable propellants in contact with the product are air or similar compositions of oxygen and nitrogen, nitrogen, oxygen and carbon dioxide. Other suitable propellants are hydrophilic ditto and mixtures of these. By hydrophilic we mean that the propellant cannot dissolve the crystal structure of the monoglycerides at storage températures between 0 and 30 C. The amount of propellant required is the amount sufficient to form a suitable foam. This is individual and depending on the composition and the desired properties of the foam and this can be evaluated by a person ski lied in the art.
In further embodiments, the foam delivery System can be presented in the form pressurized packaging. This can be of an open interior where ail ofthe propellant is mixed with the product or in the form of a bag on valve container where the product is contained in a small polymeric/sandwich membrane bag inside the container and thus separated from the bulk of the propellant, as shown in Figs. 1 and 2. Different propellants can be used inside and outside this bag to optimize foam properties and product stability. Propellants that are not in contact with the composition during storage can be the earlier mentioned hydrophilic ones or any suitable lipophiillic propellant such as butan, propan etc, including mixtures with the earlier mentioned hydrophilic ones.
In preferred embodinents the foam delivery System presented in a pressurized container, packaging, or the like, comprises a foam guiding conduit adapted to provide adéquate delivery to ail areas of the body cavity to be treated. Based upon the teachings of the présent disclosures sélection of conduit can be made by one skilled in the art.
In yet another preferred embodiment of the invention the product is mixed with the blowing gas at ambient pressure. Such product can be stored in nonpressurized containers exemplified but not limited to pumps intended for storage and delivery of détergents and soaps.
Generally a foam guiding conduit is adapted when applying to a body cavity to resuit in a coverage of the inner cavity surface greater than that achievable in the absence of the conduit, advantageously complété coverage. In alternative embodiments the coverage can be selected from more than any of: 50%, 60%, 70%, 80% and 90%.
Any desired active agent utilized for treating and/or preventing a condition, disease, infection, or other, in a body cavity can be used in the présent invention in their pharmaceutically effective amounts.
In another embodiment the foam can be used for the treatment of local diseases such as infections by bacteria, fungi, virus, parasites or other microorganisms. Non-limiting examples of such infections are bacteria orfungal vaginosis and sexually transmitted infections such as, gonorrhea, syphilis and chlamydia. Other examples are otitis and nasal infections as well as prophylactic treatment against infection or inflammation after surgery. Another example is prophylaxtic use of the product in orderto avoid fungal infections caused by shaving (tinea barbae) involving Dermatophytes or Malassezia folliculitis.
Other medical indications suitable for treatment by this invented product are local inflammatory processes exemplified but not limited to vulvovaginitis. Suitable compounds are steroids and nonsteroidal anti-inflammatory agents.
Other examples of suitable medical indication are psoriasis and useful medical agents that can be incorporated in the foam formulation are vitamin D3 antagonists and steroids. Compounds useful in the treatment of eczema can also benefit from the introduction into the invented foam formulation. Examples of such compounds are steroids, NSAIDs and COX 2 inhibitors.
Yet other medical indications are préparations for the treatment of ulcers or réduction of scar formation after ulcers generated by surgery or by other causes. Non-limiting examples of suitable compounds are collected from the group of growth factors or compounds having effect on release of growth factors.
Fungal infections on skin or wounds or in body cavities can be treated using the invented foam including an antifungal agent effective agains dermatophytes or candida species.
Another medical condition that can be treated with the invented formulation is urinary incontinence. Non-limiting examples of suitable substances are anticholineric compounds such as Oxybutynin, Tolterodine, Darifenacin,Solifenacin, Trospium, Fesoterodine, and bladder relaxing compounds such as Myrbetriq.
The administration of foam to body cavities can be used to treat a systemic disease. Application of a foam to a body cavity can create a large application area and favorable conditions for pénétration though or into mucus membranes.
In yet other embodiments of the invention we hâve found that surface active agents may be useful in the composition. These agents can improve foam properties but also increase the contact between waxy surfaces such as in the ear, and the product.
The invention also relates to methods of treating a condition in a body cavity comprising forming a foam from the foam-forming composition comprising HP, hydrogen peroxide, monoglyceride crystals in an amount to form a foam, at least one acid and/or buffer which is présent in an amount to provide a pH of 3 to 5 within a body cavity and water by blowing the foam with a blowing agent in an amount to blow the foam-forming composition and form the foam. The methods include applying the foam to a body cavity to coat tissues in the body cavity with the foam-forming composition with the blowing agent and/or allowing the body to heat the foam to a décomposition température of the foam, wherein the foam dégradés and releases the hydrogen peroxide to the tissues in the body cavity at a pH of 3 to 5, and/or guiding the foam by a foam guiding conduit.
The invention also relates to a method of delivering an active agent to tissues in a body cavity comprising forming a foam from a foam-forming pharmaceutical composition for delivering an active to a body cavity comprising water, an active agent, and solid lipid crystals suspended in the water, the solid lipid crystals having a melting point in their crystalline State of less than 37°C and more than 25°C by blowing the foam-forming composition with a blowing agent. Applying the foam to a body cavity to coat tissues in the body cavity with the foam-forming composition with the blowing agent. Allowing the body to heat the foam to a décomposition température of the foam, wherein the foam dégradés and releases the active agent to the tissues in the body cavity, and/or guiding the foam by a foam guiding conduit.
Effects of Hydrogen Peroxide.
One problem in the treatment of sexually transmitted and other vaginal infections, exemplified but not limited to, gonorrhea and bacterial vaginosis is the development of résistance towards antibiotics. The antibiotics are spécifie in their action and operate on the bacteria cell membrane and small alterations in the cell wall synthesis can lead to inactivation of the antibiotic. Antiseptics with less spécifie action such as peroxides, halogens such as chlorine and iodine, phénols and alcohols, as well as phenolic and nitrogen compounds are less likely to generate résistance due to their general bactericidal effect. However, the lower specificity leads in general to larger risk for toxicity. Of the listed antiseptics most of them are unsuitable for administration into body cavities. One that is suitable is hydrogen peroxide (HP).
It is known that peroxides and in particular HP is an effective antiseptie compound and that most microorganisms are sensitive to HP. We hâve found that the présent invention is capable of eradicating the relevant bacteria when présent in a pharmaceutically effective amount. Preferred amounts of HP include from 0.05 to 1 %, more préférable 0.05 to 0.7 % and most préférable 0.1 to 0.6%. In this application, the content of an ingrédient is given in % by weight based on the total weight of the composition.
HP has been administered to humans for over 100 years and one problem that has limited the use of HP has been the auto-oxidation of hydrogen peroxide. This phenomenon leads to a rapid dégradation of HP as soon as HP is exposed to reactive matter. The fast reaction leads to boiling, development of oxygen a dégradation product of HP, and the HP is consumed within minutes or seconds. With the presence of crystalline acyl monoglycerides, preferably from C12 to C14, the rate of dégradation of HP at the site of action can be regulated and optimized for maximum effect. This procedure has been described in the literature for use on skin at higher concentrations of HP. This procedure has however not been demonstrated for use in body cavities, and neitherfor low amounts of HP, such as 0.5% and below.
HP can be enzymatically degraded, e.g. by catalases and there are at least two sources of catalase in vaginal and uréthral infections and that is the naturally occurring catalase from eukaryote cells and the other is the catalase generated by the pathogens, i.e. N. gonorrhoea and G. vaginalis. The catalase is effective at a pH over 5 and in orderto avoid this effect the product advantageously contain an alpha hydroxyl acid in an amount sufficient to keep the pH in the body cavity between 3 and 5, preferably between 3.5 and 4.5. Any acid or buffer System suitable for application to a body cavity can be utilized. In the case of the vagina, a preferred acid is lactic acid since lactic acid is already présent in the vagina. Other preferred acidifying agents are polymers and oligomers of lactic acid, glycolic acid and acrylic acids or combinations thereof.
The amount of alpha hydroxyl acid in the composition, combinations of monomers and/or oligomers and/or polymers présent is preferably 1 to 10%, more preferably 2 to 7%, and most preferably 3 to 6%. In orderto operate inside a smaller pH range some of the acid may be replaced by with the sait of the acid or with bases to make a buffer. The final pH should preferably be between 3 and 6, more preferably between 3.5 and 5 and most preferably between 3.5 and 4.5 when exposed to 1 to 10 parts of vaginal fluid.
A nonlimiting example of a alpha hydroxyl acid is Lactic Acid.
Another important property of the présent invention is the ability to regulate pH at the application site. The pH in a healthy vagina is about 4 while the main site of gonorrhea infections for men, the urinary tube, is between 8 and 5 with good opportunities for catalase activity. The présent invention contains alpha hydroxyl acids with the purpose of keeping the intra-vaginal pH sufficiently low to inhibit the catalases. Preferably, the amount of acid is sufficient to provide a pH below 5 in order to inhibit catalase activity generated by the pathogens or by invading cells, local orfrom plasma. In orderto provide a pH between 3 and 5 the use of at least one buffer based on alpha hydroxyl acids are preferred. A preferred buffer is lactic acid buffer. Preferred pHs are from pH 3 to 5 and more preferably a pH of 3.5 to 4.5. The buffer is preferably présent in an amount to be able to keep the pH below 5 when diluted in vaginal or uréthral fluids.
Treatment of skin diseases require may a low pH, between 5 and 5.5, to avoid local irritation. Any physiologically acceptable buffer System can be used for this purpose and a skilled artisian can evaluate the amount of buffer needed.
Stabilizers for Hydrogen Peroxide
The présent invention contains at least one, preferably at least two, and more preferably several stabilizers for HP in order to avoid auto-oxidation. Stabilizers for HP are wellknown and any suitable stabilizer can be utilized.
A polycarboxylic acid having a chain length of 2 to 6 carbon atoms, preferably oxalic acid has shown stabilizing effects on HP. The acids can be added to the formulation as salts or as the acid. A most preferred acid of this type is oxalic acid. The acids are preferably added in concentrations between 0.05 and 0.5 % and more preferably 0.1 to 0.3 %.
Tin, in the form of a sait, either as sodium sait or as a pyrophosphate can be présent in an amount of 0.005 to 0.05% or preferably 0.01 to 0.03 % corresponding to the amount of tin.
Salicylic acid can be added in an amount of 0.02 to 0.5%, preferably 0.05 to 0.2%.
Salicylic acid can also be added as a sait of salicylic acid. Concentrations of Salicylic acid above 0.5% are preferably avoided since above this level pharmacological effects of Salicylic acid could be expected.
The présent invention can be adjusted to a pH with respect to the stability of HP. In this stabilizer combination, the preferred pH during storage was found to be 3.5 to 4.5, which was unexpected in view of the prior art teachings e.g.those of Schumb et al and other authors referred to in the background section. If not buffered the pH in the présent invention typically increases after manufacture, e.g. a formulation that immediately after manufacture has a pH of 4.5 will typically increase to pH 5 after a few weeks storage and remain below pH 5.3 for the remaining shelf life period.
Additional stabilisers such as pyrophosphate and sesquestrants, such as but not limited to EDTA and phosphonic acids as well as salicylic acid, are also possible to incorporate into the formulation. Physical stabilisers, against sédimentation of the lipids, such as polar surfactants with HLB over 20 and thickeners such as polyacrylic acid dérivatives can also be added to the formulation to improve its properties. Traditional dermatological agents such as glycerol and propyleneglycol can be added.
Other active principles may hâve other requirements on stabilizers. The use of vitamin or dérivatives thereof, gallates or other known stabilizers are possible to include in the invented formulations.
Examples:
Some of the products manufactured as examples has been subject to microscope investigation to evaluate foam forming and foam stability. The has been done in light microscope, Motic B3 professional, using a magnification of 4x10. The airbubbles found were ail irregular, no spheres, in shape indicating that the structure forming the airbubbles are in solid state and not liquid.
Example 1.
The formulations in table 1 were manufactured and tested for content of HP by a permanganate titration method, USP, assay for HP. The manufacture was performed according to the following procedure. EDTA, sodium stannate, sodium pyrophosphate, and sodium oxalate were dissolved in water. If applicable, thickening agents are included at this point. Lactic acid and sodium hydroxide were added and pH adjusted. The monoglycerides were added and the mixture was heated to 70 to 75 C and kept there for 15 minutes while stirring. After 15 minutes slow cooling, less than 5 C per minute, was applied to about 35 when crystallisation occurred followed by an increase in température. After the crystallisation was completed hydrogen peroxide was added. The products were packed in spray containers consisting of a métal can and a laminate internai bag. The product was premixed with air and filled insido the bag on valve and additional air up to a pressure of 5 bars.The product was stored at 30 °C, 25 °C and 3 to 8 °C Analysis of the content of HP was made by a titration method including dissolution of the compositions in acetic acid and titration to color shift by potassium permanganate.
Table 1 Formulations for stability testing (% w/w).
A | D | E | F | |
EDTA | 0.05 | 0.05 | 0.05 | 0.05 |
Sodium pyrophosphate | 0.025 | 0.025 | 0.025 | 0.025 |
Sodium stannate | 0.04 | 0.04 | 0.04 | 0.04 |
Sodium oxalate | 0.14 | 0.14 | 0.14 | 0.14 |
Lactic acid (90 %) | 5.00 | 5.00 | 5.00 | 5.00 |
Glycerol monolaurate | 0.625 | 2.5 | 2.5 | 5.0 |
Glycerol monomyristate | 1.875 | 7.5 | 7,5 | 15.0 |
H2O2 | 0.3 | 0.3 | 0.1 | 0.5 |
10M NaOH | 3.00 | 3.00 | 3.00 | 3.00 |
HPLC water | To 100 | To 100 | To 100 | To 100 |
PH | 3.5 | 3.5 | 3.5 | 3.5 |
Stability* | ||||
Initial | 3.20 | 3.31 | 1.24 | 5.29 |
30 C 30 days | 2.74 | 2.77 | 0.87 | 4.56 |
Remaining amount of hydrogen peroxide (mg/g)
Example 2, Foam forming.
We hâve studied the effect of the amount of lipids on the ability to form a foam and the stability of HP. The formulations were manufactured according to example 1 and aérosols were produced by, under pressure, adding 0.25 % of air or a mixture 50/50 of pharmaceutical grade propane and butane into an aérosol container having an inner container of a polymer protecting the product against the métal material in the container.
Table 2. Foaming versus amount of monoglycerides(%)
Ingrédient | 1 | 2 | 3 | 4 |
1-glycerylmonolaurate | 2.5 | 2.5 | 5 | 1.25 |
1-glycerylmonomyristate | 7.5 | 7.5 | 15 | 3.75 |
Myrj 59 | 0.1 | 0.1 | 0.1 | 0.1 |
Lactic acid | 3.0 | 3.0 | 3.0 | 3.0 |
Sodium hydroxide | 0 | 0 | 0 | 0 |
Purified water to | 100 | 100 | 100 | 100 |
pH | 4 | 4 | 4 | 4 |
Butane/propane | 8 | |||
Air to pressure (atm)* | 5.5 | 5.5 | 5.5 |
Corresponds to about 0.25 g of air.
Ail three batches that contain air produced a white solid foam when released from the can, which was observed by the naked eye. The foam produced by the batch that contained butane/propane produced an inhomogeneous off whit/yellow foam. The product was tested for crystallinity of monoglycerides using a DSC, differential scanning calorimeter.
The products that contain air show a level of crystallinity of more than 70 %. The container that was pressurized by butane demonstrated a level of crystallinity of less than 50%.
Example 3
Effect of propellant on hydrogen peroxide stability Manufacture: EDTA and the sodium salts were dissolved in a major part, 75%, of the water. Lactic acid and sodium hydroxide were added and pH adjusted. The monoglycerides were added and the mixture was heated to 70 to 75 C and kept there for 15 minutes while stirring. After 15 minutes slow cooling, less than 5 C per minute, was applied to about 35 C when crystallisation occurred followed by an increase in température. After the crystallisation was completed a hydrogen peroxide and the remaining water was added. The products were packed in spray containers consisting of a métal can and a aluminium/polymer laminate internai bag. The same propellant was used in and outside the laminate bag. When filing butane and propane mixtures a weight is filled but when air is used as propellant it is filled up to a determined pressure. The reason is that propane and butane are fluids at a pressure of 3 to 6 atm depending on the mixture while air turns into a fluid at about - 190 C.
Table 3. Compositions
Ingrédients | 3:1 | 3:2 | 3.3 |
Monolaurine | 2.5 | 4.5 | 4.5 |
Monomyristine | 7.5 | 13.5 | 13.5 |
EDTA | 0.05 | 0.05 | 0.05 |
Sodium pyrophosphate | 0.025 | 0.025 | 0.025 |
Sodium stannate | 0.04 | 0.04 | 0.04 |
Sodium oxalate | 0.14 | 0.14 | 0.14 |
Hydrogen peroxide | 0.314 | 0.306 | 0.335 |
Lactic acid | 3 | 3 | 3 |
10M NaOH | To pH 3.5 | To pH 3.5 | To pH 3.5 |
Water to | 100 | 100 | 100 |
Air | To 5.5 atm | To 5.5 atm | |
Propane/butane 50/50 | 8 | ||
Remaining after 2 month at 25 C (%) | 0.303 | 0.306 | 0.285 |
A decrease in hydrogen peroxide content was very low or not présent for batches propelled by air. When butane/ propane was used as propellant the stability of hydrogen peroxide was significantly lower, i.e. the hydrogen peroxide content decreased significantly.
Example 4 stability of BPO
Table 4. Stability of BPO in the invented composition in a pressurized container.
Components | g/100 g product |
EDTA | 0.05 |
Lactic acid (90 %) | 3.00 |
Glycerol monolaurate | 2.5 |
Glycerol monomyristate | 7.5 |
Benzoyl peroxide | 5.0 |
10M NaOH | 3.00 |
HPLC water | To 100 |
Propellant, airto 5.5 atm | About 0.25 |
PH | 4.2 |
Stability* | |
Initial | 50 |
25 °C 3 months | 48 |
2-8 °C 3 months | 50.1 |
* Remaining amount of BPO (mg/g)
Manufacture: EDTA, was dissolved in part of the water. Lactic acid and sodium hydroxide were added and pH adjusted. The monoglycerides were added and the mixture was heated to 70 to 75 C and kept there for 15 minutes while stirring. After 15 minutes slow cooling, less than 5 C per minute, was applied to about 35 C when crystallisation occurred followed by an increase in température. After the crystallisation was completed a suspension of BPO in water was added. The products were packed in spray containers consisting of a métal can and a aluminium/polymer laminate internai bag. The product was premixed with air and filled inside the bag on valve and additional air up to a pressure of 5.5 atm. The product was stored at 25 °C and 3 to 8 °C Analysis of the content of BPO was made by a HPLC-UV method. At 25 °C the product showed no dégradation after 1 month storage.
The propellant (blowing agent) amount noted in table 4 refers to the amount of propellant in contact with the composition. The product demonstrated a slight dégradation at 25 °C but is stable at 2 to 8 °C.
Example 5.
Melting point of foam was determined.
The formulations according to table 5 were manufactured according to Example 1.
Table 5. Formulations for melting point test.
Ingrédients | G | H 1 | |
1 -Glycerylmonomyristate | 6 | 9 | |
1 -Glycerylmonolaurate | 3 | 9 | |
Lactic acid | 3.6 | 3.6 | 3.6 |
Hydrogen peroxide | 0.27 | 0.27 | 0.27 |
Sodium hydroxide | 0.9 | 0.9 | 0.9 |
Water | 77.23 | 77.23 | 77.23 |
Melting point (°C) | 34 | 41 | 39 |
Method and results: The melting of the formulations was tested by differential scanning calorimetry, DSC. A DSC 7 was used and about 5 mg of each formulation was weighed and put in aluminium containers. The melting peak of the préparations were determined by first cooling to about OC and then heating to 50C at a rate of 5C per minute.
The results show that a combination of the two monoglycerides makes the composition to 5 melt when heated to body température and provide even application of the active to the affected tissue in the body cavity.
Example 6 Manufacture of the formulation and content of lipids.
Table 6: Compositions (g)
Invented composition | 1A | 1B |
EDTA | 0.050 | 0.050 |
Sodium pyrophosphate | 0.025 | 0.025 |
Sodium stannate | 0.040 | 0.040 |
Sodium oxalate | 0.14 | 0.14 |
Lactic acid | 3.00 | 3.00 |
Glycerol monolaurate | 0.2 | 7 |
Glycerol monomyristate | 0.4 | 21 |
NaOH | 0.70 | 0.70 |
Hydrogen peroxide 30 w% | 1.00 | 1.00 |
Propellant | 10 | 10 |
HPLC water | 94.445 | 67.045 |
The formulations were manufactured by heating of water to 75 C, dissolving the salts and lactic acid in said water, the first 5 items on the ingrédient list, and addition of the monoglycerides. After 15 minutes at 75 C the monoglycerides are melted and the mixture 15 is cooled slowly to about 30 C to obtain crystallization and the cooling is stopped. After crystallization, visible as an increase in reflection of light from the composition, cooling to ambient température, < 25 C, was undertaken. The pH was adjusted with sodium hydroxide and hydrogen peroxide was added. The manufactured compositions were packed in bulk containers.
Example 7
Products, suspensions of crystalline lipids in water manufactured according to Example 1 and with composition according to table 5 were packed under pressure in two types of pressure containers, bag on valve which is a dual compartment packaging and a single compartment packaging device. Packing in bag on valve, BOV, pressure packs were made by using a manual filling equipment. At first the composition was filled, then gas was filled outside the bag on valve and finally the gas inside the bag on valve (in contact with the composition). The gas used in contact with the composition was compressed air as well as the gas outside the bag.
Table 7. Composition, one compartment pressure container.
Type | Amount | |
Product see example 1 | Formulation 1D | 10g |
Gas (propellant) | Air to 5.5 atm | About 0.1 g |
Table 8. Composition, bag on valve.
Type | Amount | |
Product see example 1 | Formulation 1D | 10g |
Gas (propellant) in bag | Air to 5.5 atm | About 0.1 g |
Gas (propellant) in pressure container | Air to 5.5 atm | About 0.1 g |
From aérosol packing point of view both types of packages are possible to use since a solid whie foam that melt at about 35 °C was generated.
Example 8, foam stability.
Two foam products, one commercial and one according to the invention, are manufactured 10 and pressure packed, and the foam stability is tested by a modification of an EP method for testing foam stability.
Table 9. Composition of invented foam (g).
Presented Invention | |
EDTA | 0.050 |
Sodium pyrophosphate | 0.025 |
Sodium stannate | 0.040 |
Sodium oxalate | 0.14 |
Lactic acid | 3.00 |
Glycerol monolaurate | 2.50 |
Glycerol monomyristate | 7.50 |
NaOH | 0.70 |
Hydrogen peroxide 30 w% | 1.00 |
HPLC water | 85.045 |
Air inside bag | 0.2 |
Air outside bag (in pressure container) | To 5.5 bar |
Table 10. Commercial foam.
Composition from US 7,749,448 | |
Dehydrated Alcohol (Ethanol), USP | 58.98 |
Cetyl Alcohol, NP | 1.16 |
Stearyl Alcohol, NP | 0.53 |
Polysorbate 60, NP | 0.42 |
Propylene Glycol, USP | 2.11 |
Purifed Water, USP | 36.69 |
Potassium Hydroxide, USP, 10% W/W soin. | 0.11 |
Air inside bag | 5.5 atm |
Air outside bag (in pressure container) | 5.5 atm |
Foam stability and adhesion test.
A glass tube, volume 60 ml, with a diameter of 26 mm was heated to 37°C in a waterbath. The glass tube was removed and was turned upside down. The foams were administered into the tube through a foam guiding conduit, see drawing, until it was full by a controlled procedure comprising initially filling the cavity volume furthest away from the opening and then withdrawing the conduit to optimize foam delivery The tube was then returned to the water bath. The spreadability, melting and adhesion to the tube surface was studied.
Results:
The invented foam filled the volume of glass tube completely and rapidly. After about 30 seconds in the water bath it started to melt and adhered to the surface. The entire internai surface of the glass tube was covered with the melted foam as observed by the naked eye. The prior art foam collapsed at contact with the surface and did not fill the volume and only a part of the inner surface of the tube was covered with the prior art foam.
Example 9. Testing of melting températures for mixed monoglycerides crystals.
Monoglyceride mixtures
Manufacture: Water was heated to 75 °C and lactic acid and then the monoglycerides were added. After 15 minutes of stirring and after melting was complété, slow cooling was applied. Cooling was stopped at 30 C when crystallization started. After crystallization, the préparation was allowed to cool to ambient température by passive cooling. The melting 10 température of the manufactured compositions was determined by differential scanning calorimetry, DSC-7 Perkin Elmer. Melting points were tested in DSC by weighing 5 mg into aluminum containers which were closed and the température was run from 0 c to 45 °C at a rate of 5 °C per minute. Melting points were estimated as onset of energy uptake. The results are shown in Table 11
Table 11: Melting point and compositions of formulations studied.
Ingrédients | A | B | C | D | E | F | G | H | I | J | K | L |
Water, purified | 36.5 | 36.5 | 36.5 | 36.5 | 36.5 | 36.5 | 36.5 | 36.5 | 36.5 | 36.5 | 36.5 | 36.5 |
Lactic acid (90%) | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 |
Glycerol-1caprylate | 3 | 9 | 3 | 9 | 3 | 9 | ||||||
Glyceryl-1laurate | 9 | 3 | 3 | 9 | 3 | 9 | ||||||
Glyceryl-1myristate | 9 | 3 | 9 | 3 | 3 | 9 | ||||||
Glyceryl-1stearate | 9 | 3 | 9 | 3 | 9 | 3 | ||||||
Total (g) | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 |
M.P. (°C) | - | 4.4* | 39.4* | - | - | 5* | 35.5 | 34.9 | - | 34.3* | - | 43.1 |
*Separation
The melting point, onset of melting, of the monoglycerides demonstrates melting at skin températures for combinations of monolaurin and monomyristin, D and E. The data also demonstrates that mixtures of monoglycerides having a différence in carbon chain length of more than 2 are not forming joint crystals. Mixtures with monocaprylate as major component melt at 4 to 5 °C, which is too low, while a combination of monomyristine and monostearate, G, melt at too high a température.
o
Example 10, formulations intended for local treatment of vaginal infections.
Table 12. Example of a composition of a 3 mg/g hydrogen peroxide vaginal foam.
Ingrédients | Quantity % (w/w) |
Hydrogen peroxide | 0.3 |
EDTA | 0.05 |
Sodium pyrophosphate | 0.025 |
Sodium stannate | 0.04 |
Sodium oxalate | 0.14 |
Glycerol monolaurate | 2.5 |
Glycerol monomyristate | 7.5 |
Lactic acid (90%) | 3.0 |
Sodium hydroxide | 3.0 |
Water demineralized | 83.745 |
Total | 100.00 |
Air to 5.5 atm | About 0.2 % |
An example of a composition of a 3 mg/g hydrogen peroxide vaginal foam in amounts retaining the properties of the composition and the foam disclosed herein was tested, to enhance properties in contact with tissue and skin in amounts retaining the properties of the composition and the foam disclosed herein, to enhance properties in contact with tissue and skin.
The active, HP, is active against most microorganisms. Only when the microorgansism can dégradé HP, e.g. by catalases or similar enzymes, the antimicrobial capacity is compromised. Since the présent formulation avoids this catalase effect, the formulation can be used broadly. Sexually ransmitted infections, STI, such as gonorrhoea and candida as well as bacterial vaginosis and trichomonas can be possible to treat successfully with the présent invention. Other infections located in the vagina, urethra, anal, oral and nasal région as well as in the ear caused by bacteria sensitive to hydrogen peroxide should be treatable with the présent invention.
Body cavity includes not only as natural cavities in contact with the surroundings such as vagina, the mouth and throat, the nasal région, the ear, urethra and rectum but also artificial body cavities such as cavities formed during surgical interventions, dialysis, introduction of prostheses or wounds etc.
Vaginal or Other Body Cavity Use of the Formulation.
The présent formulation can be adapted for use in body cavities for the treatment of infections caused by anaérobie bacteria. Examples of suitable body cavities are the vagina, the urinary tube, the anal and the oral cavity. Also infections in the nose and in ears may be treated with this formulation.
Examples of Infections that can be Treated with HP.
However, the cavity should be able to access from the outside without causing trauma which excludes cavities in the brain heart and the spine as well as the upper gastrointestinal channel.
A formulation useful for the treatment of vaginal infections is presented in table 8. The formulation is useful for the treatment of infections caused by microorganisms that are sensitive to hydrogen peroxide. Non limiting examples of such bacteria are associated with bacterial vaginosis, fungal infections, gonorrhoea, syphilis and chlamydia. It is also locally effective against virus.
Example 11. Formulation of steroids in foam
This type of foam is useful for the treatment of inflammatory diseases such as psoriasis, dermatitis and other types of eczema.
Table 13. formulation for the treatment of eczema.
Ingrédient g/100g
1-Glycerylmonolaurate5
1-Glycerylmonomyristate15
Mometasone furanoate0.1
Glycerol3
Water76 9
Airto5.5atm0.25
Manufacture was performed by heating the monoglycerides with water to 75 C and stirring 5 for 15 minutes, followed by addition of glycerol and mometasone furanoate and then slow cooling to crystalisation at about 35 C. The product was then cooled to ambient température. Testing of foaming capacity and foam quality was made by whipping air into the bulk cream at ambient pressure. A method forthis has been developed and after 30 seconds a foam was formed. The foam was stable for more than 30 days in normal atmosphère at 25 C as evaluated by microscope. The entrapped airbubbles suggested that the structure was made up by planar crystals and not by a liquid bilayer film.
Example 12, Foam for treatment of urinary incontinence
Table 14. formulation for the treatment of urinary incontinence.
Ingrédient | g/100g |
1 -Glycerylmonolaurate | 5 |
1 -Glycerylmonomyristate | 15 |
Oxybutynine chloride | 0.1 |
Lactic acid | 1 |
Glycerol | 3 |
Water | 75.9 |
Air (microgram) | 60 |
Manufacture was performed by heating the monoglycerides with water to 75 C and stirring for 15 minutes, followed by addition of glycerol and Oxybutynine chloride and then slow 5 cooling to crystalisation at about 35 C. The product was then cooled to ambient température. Testing of foaming capacity and foam quality was made by whipping air into the bulk cream at ambient pressure. A method for this has been developed and after 30 seconds a foam was formed.. The foam was stable for more than 30 days in normal atmosphère at 25 C as evaluated by microscope. The entrapped airbubbles suggested 10 that the structure was made up by planar crystals and not by a liquid bilayer film.
Example 13, Foam for treatment of psoriasis
Table 15. formulation for the treatment of psoriasis.
Ingrédient | g/100g |
1 -Glycerylmonolaurate | 5 |
1 -Glycerylmonomyristate | 15 |
Calcipotriol | 0.005 |
Glycerol | 3 |
Water to | 100 |
Air (microgram) | 110 |
Manufacture was performed by heating the monoglycerides with water to 75 C and stirring for 15 minutes, followed by slow cooling to crystalisation at about 35 C. The product was then cooled to ambient température. Calcipotriol and glycerol was added after crystallization. Testing of foaming capacity and foam quality was made by whipping air into the bulk cream at ambient pressure. A method for this has been developed and after 30 seconds a foam was formed. The was stable for more than 30 days in normal atmosphère at 25 C as evaluated by microscope. The entrapped airbubbles suggested that the structure was made up by planar crystals and not by a liquid bilayer film.
Example 14, Foam for treatment of itch.
Table 16. formulation for the treatment of itch.
Ingrédient g/100g
1-Glycerylmonolaurate5
1-Glycerylmonomyristate15
Doxepin5
Glycerol3
Water72
Air (microgram)37
Manufacture was performed by heating the monoglycerides with water to 75 C and stirring for 15 minutes, followed by addition of glycerol and Doxepine and then slow cooling to crystalisation at about 35 C. The product was then cooled to ambient température. Testing of foaming capacity and foam quality was made by whipping air into the bulk cream at ambient pressure. A method for this has been developed and after 30 seconds a foam was formed. The foam was stable for more than 30 days in normal atmosphère at 25 C as evaluated by microscope. The entrapped airbubbles suggested that the structure was made up by planar crystals and not by a liquid bilayer film. Fig. 1 is a picture of the foam and Fig. 2 is a picture of the foam after one month.
Example 15 Foam for treatment of local inflammation
Table 17. formulation for the treatment of local inflammation.
Ingrédient | g/100g |
1 -Glycerylmonolaurate | 5 |
1 -Glycerylmonomyristate | 15 |
Diclofenac diethylamine | 1.16 |
Propyleneglycol | 5 |
Water to100 | 100 |
Air (microgram) | 37 |
Manufacture was performed by heating the monoglycerides with water to 75 C and stirring for 15 minutes, followed by addition of glycerol and Diclofenac diethylamine and then slow cooling to crystalisation at about 35 C. The product was then cooled to ambient température. Testing of foaming capacity and foam quality was made by whipping air into the bulk cream at ambient pressure. A method for this has been developed and after 30 seconds a foam was formed. The foam was stable for more than 30 days in normal atmosphère at 25 C as evaluated by microscope. The entrapped airbubbles suggested that the structure was made up by planar crystals and not by a liquid bilayer film.
Example 16 Foam for treatment of fungal infections
Table 18. antifungal formulation
Ingrédient | g/100g |
1 -Glycerylmonolaurate | 5 |
1 -Glycerylmonomyristate | 15 |
Terbinafine HCl | 1 |
Propyleneglycol | 7 |
Urea | 1 |
Lactic acid | 2 |
Water toi 00 | 100 |
Air (microgram) | 12 |
Manufacture was performed by heating the monoglycerides with water to 75 C and stirring for 15 minutes, followed by addition of glycerol and Terbinafine HCl stirring for another 5 minutes and then slow cooling to crystalisation at about 35 C. The product was then cooled to ambient température. Testing of foaming capacity and foam quality was made by whipping air into the bulk cream at ambient pressure. A method for this has been developed and after 30 seconds a foam was formed. The foam was stable for more than 30 days in normal atmosphère at 25 C as evaluated by microscope. The entrapped airbubbles suggested that the structure was made up by planar crystals and not by a liquid bilayer film.
Example 17 Foam for dry and irritated skin and body cavities
Table 19. Formulation for dry skin
Ingrédient | g/100g |
1 -Glycerylmonolaurate | 5 |
1 -Glycerylmonomyristate | 15 |
Lactic acid | 2 |
Glycerol | 5 |
Myrj 59 | 0.1 |
Water to | 100 |
Air (Microgram) | 60 |
Manufacture was performed by heating the monoglycerides with water to 75 C and stirring for 15 minutes, followed by addition of Lactic acid, glycerol and Myrj 59, and then slow cooling to crystalisation at about 35 C. The product was then cooled to ambient température. Testing of foaming capacity and foam quality was made by whipping air into the bulk cream at ambient pressure. A method for this has been developed and after 30 seconds a foam was formed. The foam was stable for more than 30 days in normal atmosphère at 25 C as evaluated by microscope. The entrapped airbubbles suggested that the structure was made up by planar crystals and not by a liquid bilayer film.
It was unexpected and surprising that the foam formed by whipping the blowing agent (such as air) into the suspension exhibited long term stability. It was also unexpected and surprising that the foam formed by allowing the blowing agent to expand and form the foam also exhibited long term stability.
Claims (2)
1· A foam-forming pharmaceutical composition for delivering active agents to the surface of the body or to body cavities comprising:
5 water;
solid lipid crystals suspended in the water, the solid lipid crystals having a melting point in their crystalline State of less than 37°C and more than 25°C; and a non-lipophilic propellant for blowing the composition and forming a foam, wherein the propellant is air or a gaseous mixture simulating air, 10 wherein the solid lipid crystals being présent in an amount to support a foam when the composition is blown by the propellant, and the composition is adapted for application to the surface of the body or the body cavity when blown so that when the foam is heated by the surface of the body or the body cavity the foam dégradés at the melting point and releases contents of the foam to tissues on the surface of the
15 body or in the body cavity; wherein the lipid crystals are a combination of glycerol monolaurate and glycerol monomyristate, where the combination of glycerol monolaurate and glycerol monomyristate is présent in an amount of 1% to 35% by weight based on the weight of the composition; and wherein the composition is under atmospheric pressure by the propellant.
2· The foam-forming composition according to claim 1, comprising an effective amount of a medically active, cosmetic or relieving agent.
3· The foam-forming composition according to claim 1, wherein the propellant is from 0.0001 to 0.5 % by weight of the composition.
4- The foam-forming composition according to claim 1, the composition is
30 packed in single or dual compartment containers; and optionally wherein the product comprises a foam guiding conduit adapted to provide vaginal delivery of the foam.
5- The foam-forming composition according to claim 1, wherein the lipid comprises at least one selected from the group consisting of monoacylglycerides
A having a carbon chain length of 10 to 16 carbons and where the relation between the monoacylglycerides are 1:20 to 20:1.
6· The foam-forming composition according to claim 2, wherein the active agent comprises hydrogen peroxide for the treatment of infections in body cavities.
7· The foam-forming composition according to the claim 2, wherein the active agent comprises anticholinergic or bladder relaxing compounds suitable for treatment of urinary incontinence.
θ· The foam-forming composition according to the claim 2, wherein the l active agent comprises anti-psoriatic drugs suitable for treatment of psoriasis.
9- The foam-forming composition according to the claim 2, wherein the active agent comprises compounds suitable for treatment of acné.
10· The foam-forming composition according to the claim 2, wherein the active agent comprises antiinflammary agents suitable for treatment of local inflammations.
1T A method of making a foam according to claim 1, comprising forming a suspension of the solid lipid crystals in the water and forming the foam by mixing the blowing agent into the suspension at ambient pressure.
12. A foam-forming composition for use in treating an infection or disease in a body cavity, wherein the foam-forming composition is according to claim 1.
13. The foam-forming composition for use in treating an infection or disease in a body cavity according to claim 12, wherein the foam-forming composition is initially in the form of a foam in the body cavity and then couverts to a liquid having a pH of 3 to 5 in the presence of body heat and the active agent comprises hydrogen peroxide.
14. The foam-forming composition for use in treating an infection or disease in a body cavity according to claim 12, wherein the body cavity is a vaginal cavity, urethra cavity, anal cavity, oral cavity, nasal cavity, or ear cavity.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/509,932 | 2017-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA20623A true OA20623A (en) | 2022-12-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2355439T3 (en) | BIOEROSIONABLE PATCH. | |
US9895311B2 (en) | Foam-forming compositions and methods for delivering an active to a body cavity | |
JP2013500239A (en) | Foamable liquid composition containing an active agent and method for producing or developing the same | |
WO2012123515A1 (en) | An ophthalmic composition | |
US20100260835A1 (en) | Pharmaceutical composition | |
KR20080045272A (en) | Topical formulations | |
US11135166B2 (en) | Foam-forming compositions for delivering an active to a body cavity | |
CN112384201A (en) | Topical compositions | |
JP2017529377A5 (en) | ||
OA20623A (en) | Foam-forming compositions for delivering an active to a body cavity. | |
RU2773520C2 (en) | Foaming compositions for delivery of active agent to body cavity | |
EP4284323A1 (en) | Composition for use in degradation of biofilm or prevention of biofilm formation | |
OA18854A (en) | Foam-Forming Compositions and Methods for Delivering an Active Agent to a Body Cavity | |
Palekar-Shanbhag et al. | Use of Medicated Foams for Skin Diseases |